IGFBP7 and Left Ventricular Mass Regression: A Sub-Analysis of the EMPA-HEART CardioLink-6 Randomized Clinical Trial
Authors' conclusion
Our results suggest that SGLT2i-mediated reverse cardiac remodelling may be independent of IGFBP7 levels.
Study context
- Population
- Patients with T2DM and CAD74 analysed
- Participants
- 97 patients
- Comparison
- Empagliflozin vs placebo, by baseline serum IGFBP7
- Primary endpoint
- Association between baseline serum IGFBP7 and change in LV mass indexed to body surface area (LVMi) on CMR, by treatment arm
- Follow-up
- 6 months
Methodological detailsexploratory sub-analysis
- Exploratory sub-analysis
Primary result
As reported in the abstract
6-month change in LVMi per 1 ng/mL higher IGFBP7
Empagliflozin
0.25
95% CI −0.17 g/m² to 0.67 g/m² · g/m²
Placebo
0.07
95% CI −0.21 g/m² to 0.35 g/m² · g/m²
Further findings
Baseline LVMi per 1 ng/mL higher baseline IGFBP7
- No association between baseline IGFBP7 and baseline LVMi: 0.14 g/m²
- 0.14 (95% CI −0.29 to 0.57 g/m²)
IGFBP7 as categorical variable (above/below median), sensitivity analysis · 6 months
- No significant association between IGFBP7, 6-month change in LVMi and treatment arm
Original publication
IGFBP7 and Left Ventricular Mass Regression: A Sub-Analysis of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. ESC Heart Fail. Published 10 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →